Details for New Drug Application (NDA): 072253
✉ Email this page to a colleague
NDA 072253 describes OXAZEPAM, which is a drug marketed by Actavis Elizabeth, Am Therap, Epic Pharma Llc, Ivax Sub Teva Pharms, Mylan, Trupharma, Watson Labs, Watson Labs Teva, Parke Davis, and Sun Pharm Industries, and is included in twenty NDAs. It is available from four suppliers. Additional details are available on the OXAZEPAM profile page.
The generic ingredient in OXAZEPAM is oxazepam. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the oxazepam profile page.
The generic ingredient in OXAZEPAM is oxazepam. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the oxazepam profile page.
Summary for 072253
| Tradename: | OXAZEPAM |
| Applicant: | Actavis Elizabeth |
| Ingredient: | oxazepam |
| Patents: | 0 |
Suppliers and Packaging for NDA: 072253
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| OXAZEPAM | oxazepam | CAPSULE;ORAL | 072253 | ANDA | Actavis Pharma, Inc. | 0228-2067 | 0228-2067-10 | 100 CAPSULE, GELATIN COATED in 1 BOTTLE (0228-2067-10) |
| OXAZEPAM | oxazepam | CAPSULE;ORAL | 072253 | ANDA | Actavis Pharma, Inc. | 0228-2069 | 0228-2069-10 | 100 CAPSULE, GELATIN COATED in 1 BLISTER PACK (0228-2069-10) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 30MG | ||||
| Approval Date: | Apr 14, 1988 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 10MG | ||||
| Approval Date: | Apr 14, 1988 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 15MG | ||||
| Approval Date: | Apr 14, 1988 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
